Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.26.4 (
RNase H
)
2,751
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Sex-determining region Y (SRY)-box protein 2 (SOX2) plays a critical role in stem cell maintenance and carcinogenesis. In addition to its function as a minor-groove DNA binding transcription factor, our previous study showed that SOX2 also acts as a RNA binding protein. In current study, we first showed that SOX2 displayed high affinity toward the mRNA encoding
S100A14
in BFTC905 and that depletion of SOX2 resulted in a decrease of
S100A14
mRNA and protein level. To characterize the RNA binding sequence recognized by SOX2, oligomer-directed
RNase H
digestion was coupled to the cross-linking before immunoprecipitation assay to demonstrate that SOX2 preferentially binds to the 3'-UTR of the
S100A14
mRNA. Using EGFP-
S100A14
3'-UTR reporters and mobility shift assay, we identified that the binding sequence on the 3'-UTR of the
S100A14
mRNA exhibits a stem-loop structure. Together, our data indicates that SOX2 enhances
S100A14
expression by binding to the 3'-UTR of the
S100A14
mRNA. Functionally, depletion of SOX2 increases growth and mobility of BFTC905. Knock-down of
S100A14
in BFTC905 also leads to an increase in the number of the cells in the S phase and higher mobility, suggesting that SOX2 suppresses cell growth and mobility through promoting the expression of
S100A14
. Together, our experimental evidence indicates that SOX2 is capable of exerting its cellular functions by functioning as an RNA binding protein in post-transcriptional regulation.
...
PMID:SOX2 suppresses the mobility of urothelial carcinoma by promoting the expression of S100A14. 2895 11